RxDoctor Payments Data

Jung Lee, MD

Cardiovascular Disease · Hendersonville, TNNPI 1104933738

Payments from drug & device makers

$44,829in general payments, 2019–2025

Across 712 payments — averaging $62.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$14K
  • Boston Scientific$11K
  • Lilly USA, LLC$9K
  • Actelion Pharmaceuticals US, Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Johnson & Johnson$1K
  • plus $7K from 35 others

What the payments were for

  • Speaking & faculty fees$31,34070%
  • Food & beverage$13,25430%
  • Education$2351%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,829 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$176,190
Medicare patients
909
Services billed
2,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide486$509,330
OpsumitMacitentan39$475,494
UptraviSelexipag26$466,780
JardianceEmpagliflozin431$464,274
WinrevairSotatercept-Csrk22$455,490
EliquisApixaban390$430,091
AdempasRiociguat31$418,354
XareltoRivaroxaban228$279,639
Repatha SureclickEvolocumab150$130,269
MounjaroTirzepatide100$119,236
TrulicityDulaglutide54$65,002
FarxigaDapagliflozin Propanediol66$58,344
EntrestoSacubitril/Valsartan37$41,761
NexlizetBempedoic Acid/Ezetimibe48$32,417
NexletolBempedoic Acid18$17,466

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$1,982$942,27465 claims
Novo NordiskOzempic$681$509,330486 claims
Boehringer IngelheimJardiance$13,645$464,274431 claims
MerckWinrevair$672$455,49022 claims
PfizerEliquis$399$430,091390 claims
BayerAdempas$487$418,35431 claims
Johnson & JohnsonXarelto$1,289$279,639228 claims
Lilly USA, LLCMounjaro, Trulicity$8,990$184,238154 claims
AstraZenecaFarxiga$718$58,34466 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$164$49,88266 claims
NovartisEntresto$293$41,76137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Hendersonville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →